$Moderna (MRNA.US)$ Nov 15, Moderna announced preliminary Ph...

Nov 15, Moderna announced preliminary Phase 1 results from its mRNA immunotherapy, mrNA-2752, in patients with solid tumors and lymphoma. Mrna-2752 is a locally injected mRNA therapy that encodes three immunomodulators. Early results showed that mrNA-2752, in combination with the anti-PD-L1 antibody durvalumab, was well tolerated at all doses and showed signs of antitumor activity.